<DOC>
	<DOCNO>NCT00002075</DOCNO>
	<brief_summary>To compare safety effectiveness fluconazole amphotericin B , alone combination flucytosine , treatment acute cryptococcal meningitis .</brief_summary>
	<brief_title>Multicenter Comparison Fluconazole ( UK-49,858 ) Amphotericin B Treatment Acute Cryptococcal Meningitis</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Flucytosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Immunosuppressant therapy . Antiviral zidovudine . Radiation therapy mucocutaneous Kaposi 's sarcoma . Prophylaxis Pneumocystis carinii pneumonia ( PCP ) include aerosol pentamidine . Concurrent Treatment : Allowed : Radiation therapy mucocutaneous Kaposi 's sarcoma . Written informed consent must obtain patient , either patient patient 's legal guardian . No prior systemic antifungal therapy cryptococcosis . Relapse prior therapy . Success prior therapy must document negative cerebrospinal fluid ( CSF ) culture end therapy . Following prior therapy , patient may receive 1 mg/kg/wk amphotericin B 4 week entry study . Prior Medication : Allowed : Immunosuppressant therapy . Antivirals zidovudine ( AZT ) . Prophylaxis Pneumocystis carinii pneumonia ( PCP ) include aerosol pentamidine . Exclusion Criteria Coexisting Condition : Patients follow exclude : Evidence acute chronic meningitis base upon etiology cryptococcosis . History allergy intolerance imidazole , azoles , amphotericin B . Moderate severe liver disease . Comatose . Unlikely survive 2 week . Any exception prohibition concomitant medication must approve Pfizer Central Research . Concurrent Medication : Excluded : Coumadintype anticoagulant . Oral hypoglycemics . Barbiturates . Phenytoin . Immunostimulants . Investigational drug approve ( license ) drug investigational indication . Any exception prohibition concomitant medication must approve Pfizer Central Research . Excluded within 4 week study entry : Received 1 mg/kg/wk amphotericin B. Concurrent Treatment : Excluded : Lymphocyte replacement . Patients follow exclude : Evidence acute chronic meningitis base upon etiology cryptococcosis . History allergy intolerance imidazole , azoles , amphotericin B . Moderate severe liver disease . Comatose . Unlikely survive 2 week . Prior Medication : Excluded : Coumadintype anticoagulant . Oral hypoglycemics . Barbiturates . Phenytoin . Immunostimulants . Investigational drug approve ( license ) drug investigational indication . Excluded within 4 week study entry : More 1 mg/kg/wk amphotericin B . Prior Treatment : Excluded : Lymphocyte replacement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1989</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Cryptococcosis</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Flucytosine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Amphotericin B</keyword>
</DOC>